



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/47, 31/445, 31/245, 31/165	A1	(11) International Publication Number: WO 98/40070 (43) International Publication Date: 17 September 1998 (17.09.98)
(21) International Application Number: PCT/US98/04912 (22) International Filing Date: 12 March 1998 (12.03.98) (30) Priority Data: 60/040,697 13 March 1997 (13.03.97) US (71)(72) Applicants and Inventors: CAMPBELL, James, N. [US/US]; 707 Hillstead Drive, Lutherville, MD 21093 (US). PAPPAGALLO, Marco [IT/US]; Apartment 151, 2809 Boston Street, Baltimore, MD 21224 (US). MEYER, Richard, A. [US/US]; 10084 Shaker Drive, Columbia, MD 21046 (US). (74) Agent: PABST, Patrea, L.; Arnall Golden & Gregory, 2800 One Atlantic Center, 1201 West Peachtree Street, Atlanta, GA 30309-3450 (US).		(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>
(54) Title: COMPOSITIONS CONTAINING CAPSAICIN OR CAPSAICIN ANALOGUES AND A LOCAL ANESTHETIC (57) Abstract <p>Methods and compositions for treating pain at a specific site with an effective concentration of capsaicin or analogues thereof are described. The methods involve providing anesthesia to the site where the capsaicin or analogues thereof is to be administered, and then administering an effective concentration of capsaicin to the joint. The anesthesia can be provided directly to the site, or at remote site that causes anesthesia at the site where the capsaicin is to be administered. For example, epidural regional anesthesia can be provided to patients to which the capsaicin is to be administered at a site located from the waist down. By pretreating the site with the anesthetic, a significantly higher concentration of capsaicin can be used. Effective concentrations of capsaicin or analogues thereof range from between 0.01 and 10 % by weight, preferably between 1 and 7.5 % by weight, and more preferably, about 5 % by weight. This provides for greater and more prolonged pain relief, for periods of time ranging from one week to several weeks. In some cases the pain relief may be more sustained because the disease that underlies the pain may improve due to a variety of factors including enhancement of physical therapy due to less pain in the soft tissues which may foster enhanced mobilization of soft tissues, tendons, and joints.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

COMPOSITIONS CONTAINING CAPSAICIN OR CAPSAICIN ANALOGUES AND A LOCAL ANESTHETIC

Field of the Invention

This application is directed to compositions and methods for
5 relieving pain at a specific site, for example, associated with inflammation
of joints, tendons, nerves, muscle, and other soft tissues, nerve injury
and neuropathies, and pain from tumors in soft tissues or bone.

Background of the Invention

Capsaicin, a pungent substance derived from the plants of the
10 solanaceae family (hot chili peppers) has long been used as an
experimental tool because of its selective action on the small diameter
afferent nerve fibers (C fibers and A-delta fibers) that are believed to
signal pain. From studies in animals, capsaicin appears to trigger C fiber
membrane depolarization by opening cation channels permeable to
15 calcium and sodium. Recently one of the receptors for capsaicin effects
has been cloned.

Although detailed mechanisms are not yet known, capsaicin
mediated effects include: (i) activation of nociceptors in peripheral
tissues; (ii) eventual desensitization of peripheral nociceptors to one or
20 more stimulus modalities; (iii) cellular degeneration of sensitive A-delta
and C fiber afferents; (iv) activation of neuronal proteases; (v) blockage
of axonal transport; and (vi) the decrease of the absolute number of
nociceptive fibers without affecting the number of non-nociceptive fibers.

Because of capsaicin's ability to desensitize nociceptors in
25 peripheral tissues, its potential analgesic effects have been assessed in
various clinical trials. However, since the application of capsaicin itself
frequently causes burning pain and hyperalgesia apart from the
neuropathic pain being treated, patient compliance has been poor and the
drop out rates during clinical trials have exceeded fifty percent. The
30 spontaneous burning pain and hyperalgesia are believed to be due to
intense activation and temporary sensitization of the peripheral nociceptors

at the site of capsaicin application. This activation and sensitization occur prior to the desensitization phase. The activation phase could be a barrier to use of capsaicin because of the pain produced.

It would be advantageous to provide methods and compositions including capsaicin or analogues thereof with effective concentrations to cause an analgesic effect without the side effects normally associated with the use of capsaicin.

It is therefore an object of the present invention to provide a method for using capsaicin or capsaicin analogues at high concentrations with a prolonged effect.

Summary of the Invention

Methods and compositions for treating pain at a specific site with an effective concentration of capsaicin or analogues thereof are described. The methods involve providing anesthesia to the site where the capsaicin or analogues thereof is to be administered, and then administering an effective concentration of capsaicin to the joint. The anesthesia can be provided directly to the site, or at remote site that causes anesthesia at the site where the capsaicin is to be administered. For example, epidural regional anesthesia can be provided to patients to which the capsaicin is to be administered at a site located from the waist down. By pretreating the site with the anesthetic, a significantly higher concentration of capsaicin can be used. Effective concentrations of capsaicin or analogues thereof range from between 0.01 and 10% by weight, preferably between 1 and 7.5% by weight, and more preferably, about 5% by weight. This provides for greater and more prolonged pain relief, for periods of time ranging from one week to several weeks. In some cases the pain relief may be more sustained because the disease that underlies the pain may improve due to a variety of factors including enhancement of physical therapy due to less pain in the soft tissues which may foster enhanced mobilization of soft tissues, tendons, and joints.

Detailed Description of the Invention

The methods and compositions described herein can be used to provide prolonged and enhanced pain relief at a specific site or sites.

There are two major aspects to the methods: providing anesthesia at the site where the pain is to be relieved, then providing an effective concentration of capsaicin at the site where the pain is to be relieved, either by direct administration to the site or administration to an adjacent site allowing for delivery or passage of the capsaicin to the site to be treated.

Examples of conditions to be treated include pain from nerve injury (neuromas and neuromas in continuity), neuropathies, pain from tendinitis, myalgias (pain originating from disease and/or inflammation of muscle), bone or joint pain associated with inflammation or caused by injury or arthritis associated with degenerative diseases, rheumatoid arthritis, and other arthritic conditions, pain associated with painful trigger points, and pain from tumors in soft tissues.

Anesthesia

Anesthesia is provided so that there is relief from pain at the site where the capsaicin is administered and/or needed. Anesthesia can be administered directly, for example, by local administration of an anesthetic such as lidocaine or bupivacaine, or at a distant location, such as by a somatic or neuraxial block.

As used herein, the term "local anesthetic" means a drug which provides local numbness or pain relief. A number of different local anesthetics can be used, including dibucaine, bupivacaine, ropivacaine, etidocaine, tetracaine, procaine, chlorocaine, prilocaine, mepivacaine, lidocaine, xylocaine, 2-chloroprocaine, and acid addition salts or mixtures thereof. 2-chloroprocaine hydrochloride may be preferred due to its short action. In some embodiments, general anesthetic can be given as well.

Delivery systems can also be used to administer local anesthetics that produce modality-specific blockade, as reported by Schneider, et al.,

Anesthesiology, 74:270-281 (1991), or that possess physical-chemical attributes that make them more useful for sustained release than for single injection blockade, as reported by Masters, et al., Soc. Neurosci. Abstr., 18:200 (1992), the teachings of which are incorporated herein. An
5 example of a delivery system include microspheres wherein the anesthetic is incorporated into the polymer in a percent loading of 0.1% to 90% by weight, preferably 5% to 75% by weight. It is possible to tailor a system to deliver a specified loading and subsequent maintenance dose by manipulating the percent drug incorporated in the polymer and the shape
10 of the matrix, in addition to the form of local anesthetic (free base versus salt) and the method of production. The amount of drug released per day increases proportionately with the percentage of drug incorporated into the matrix (for example, from 5 to 10 to 20%). Other forms of the polymers include microcapsules, slabs, beads, and pellets, which in some cases can
15 also be formulated into a paste or suspension.

The delivery systems are most preferably formed of a synthetic biodegradable polymer, although other materials may also be used to formulate the delivery systems, including proteins, polysaccharides, and non-biodegradable synthetic polymers. It is most preferable that the
20 polymer degrade *in vivo* over a period of less than a year, with at least 50% of the polymer degrading within six months or less. Even more preferably, the polymer will degrade significantly within a month, with at least 50% of the polymer degrading into non-toxic residues which are removed by the body, and 100% of the anesthetic and glucocorticoid
25 being released within a two week period. Polymers should also preferably degrade by hydrolysis by surface erosion, rather than by bulk erosion, so that release is not only sustained but also linear. Polymers which meet this criteria include some of the polyanhydrides, poly(hydroxy acids) such as co-polymers of lactic acid and glycolic acid wherein the
30 weight ratio of lactic acid to glycolic acid is no more than 4:1 (i.e., 80% or less lactic acid to 20% or more glycolic acid by weight), and polyorthoesters containing a catalyst or degradation enhancing compound,

for example, containing at least 1% by weight anhydride catalyst such as maleic anhydride. Other polymers include protein polymers such as gelatin and fibrin and polysaccharides such as hyaluronic acid. Polylactic acid is not useful since it takes at least one year to degrade *in vivo*. The polymers should be biocompatible. Biocompatibility is enhanced by recrystallization of either the monomers forming the polymer and/or the polymer using standard techniques.

Other local carrier or release systems can also be used, for example, the lecithin microdroplets or liposomes of Haynes, et al., Anesthesiology 63, 490-499 (1985), or the polymer-phospholipid microparticles of U.S. Patent No. 5,188,837 to Domb.

Methods for manufacture of suitable delivery systems for administration of the local anesthetic are known to those skilled in the art. The formulations may also be designed to deliver both the anesthetic and the capsaicin, either simultaneously or sequentially.

Capsaicin Compositions

Suitable capsaicin compositions include capsaicin (*trans* 8-methyl-N-vanillyl-6-noneamide) or analogues thereof in a concentration between about 0.01 and 10% by weight, preferably between 1 and 7.5% by weight, and more preferably, about 5% by weight, to effectuate prolonged relief.

As used herein, the terms "capsaicin" and "capsaicin-like compound" include capsaicin and capsaicin analogues, unless otherwise specified. Analogues of capsaicin with similar physiological properties, i.e., triggering C fiber membrane depolarization by opening of cation channels permeable to calcium and sodium, are known. For example, reinsiferatoxin is described as a capsaicin analogue in U.S. Patent No. 5,290,816 to Blumberg. U.S. Patent No. 4,812,446 to Brand (Procter & Gamble Co.) describes other capsaicin analogues and methods for their preparation. U.S. Patent No. 4,424,205 cites capsaicin-like analogues. Ton et al., Brit. J. Pharm. 10:175-182 (1955) discusses the pharmacological actions of capsaicin and its analogues.

Useful capsaicin compositions can be prepared by mixing capsaicin or analogues thereof to a desired concentration by weight, in a pharmaceutically acceptable carrier for intra-articular *vide supra* administration (i.e., administration to a joint). Such carriers are well known to those of skill in the art, and include saline and phosphate buffered saline.

Where a capsaicin analogue is selected to replace some or all of the capsaicin, the analogue can be selected from those analogues with similar physiological properties to capsaicin as are known in the art. Compositions including such a high concentration of capsaicin or analogues thereof should be handled with care.

Methods of Treatment

The anesthetic is administered in the preferred embodiment by direct injection to the site where the capsaicin is to be administered, for example, by injection of the capsaicin analogue directly in the diseased or pain producing structure or the injured nerve or the nerve that provides innervation to the painful area, or to effect a regional block of the area including the site where the capsaicin is to be administered. In the embodiment wherein the anesthetic is administered as microspheres, the microspheres may be injected through a trochar, or the pellets or slabs may be surgically placed adjacent to nerves, prior to surgery or following repair or washing of a wound. The microspheres can be administered alone when they include both the capsaicin and local anesthetic or in combination with a solution including capsaicin in an amount effective to prolong nerve blockade by the anesthetic released from the microspheres. The suspensions, pastes, beads, and microparticles will typically include a pharmaceutically acceptable liquid carrier for administration to a patient, for example, sterile saline, sterile water, phosphate buffered saline, or other common carriers.

Preferred methods of administering the anesthetic include injection of the anesthetic into the epidural space adjacent to the spine for pain originating below a patient's wrist, or directly into a joint for pain

originating above the patient's waist. The prior administration of a proximal neural block sufficiently desensitizes C fibers to the expected pungent side effects of the subsequent capsaicin administration.

5 The expected side effects of the high dose application of the capsaicin composition are believed to be from the intense nociceptor discharge occurring during the excitatory phase before nociceptor desensitization. However, the prior administration of an anesthetic *vide supra* such as a nerve block, proximally or directly to the site of administration, eliminates or substantially reduces such side effects. If
10 some "breakthrough pain" occurs despite the anesthetic, this pain may be treated by administering an analgesic such as a narcotic analgesic (i.e., the various alkaloids of opium, such as morphine, morphine salts, and morphine analogues such as normorphine). The administration of the capsaicin composition can be repeated if necessary. Suitable injection
15 volumes of capsaicin compositions to be delivered range from between about 0.1 and 20 ccs, depending on the site to be treated.

The administration of the anesthetic along with the subsequent administration of capsaicin alleviates pain at the site for a prolonged period of time. Patients can be monitored for pain relief and increased
20 movement, in the situation where treatment is in a joint. The treatment can be repeated as necessary to control the symptoms.

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments to the methods described herein. Such equivalents
25 are intended to be encompassed by the following claims. The references cited herein are hereby incorporated by reference.

We claim:

1. A method for providing relief from pain at a specific site comprising:

- a) administering an effective amount of a local anesthetic to relieve the pain associated with administration of capsaicin to the site, and
- b) administering to the site capsaicin or capsaicin analogue in a concentration between about 0.01 and 10% by weight to prevent pain at the site due to the administration of the capsaicin or capsaicin analogue.

2. The method of claim 1, wherein the concentration of the capsaicin is between 1 and 7.5% by weight.

3. The method of claim 2, wherein the concentration of the capsaicin is about 5% by weight.

4. The method of claim 1, wherein the pain results from nerve injury or neuropathies.

5. The method of claim 1 wherein the pain results from tendinitis, myalgias (pain originating from disease and/or inflammation of muscle), or bone or joint pain associated with inflammation or caused by injury or arthritis associated with degenerative diseases, rheumatoid arthritis, and other arthritic conditions.

6. The method of claim 1 wherein the pain is associated with painful trigger points.

7. The method of claim 1 wherein the pain is from tumors in soft tissues.

8. The method of claim 1, wherein the anesthetic is administered as a regional, somatic or neuraxial block.

9. The method of claim 1, wherein the anesthetic is administered directly to the site

10. The method of claim 1, further comprising administering a narcotic analgesic to further inhibit the irritant effects of the capsaicin.

11. A kit for treatment of pain comprising:

a) an anesthetic in a pharmaceutically acceptable carrier for administration to a patient; and

b) capsaicin or capsaicin analogues in a pharmaceutically acceptable carrier for administration to a patient at a painful site, in an amount effective to alleviate the pain.

12. The kit of claim 11 wherein the anesthetic is a local anesthetic.

13. The kit of claim 11 wherein the anesthetic is a general anesthetic.

14. The kit of claim 11 wherein the anesthetic is formulated to cause a regional, somatic or neuraxial block.

15. The kit of claim 11 wherein the anesthetic and capsaicin are formulated together.

16. The kit of claim 11 wherein the anesthetic is provided in a controlled release formulation.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 98/04912

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/47 A61K31/445 A61K31/245 A61K31/165

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 997 853 A (BERNSTEIN JOEL E) 5 March 1991 see abstract; claim 1 ---	1-16
X	US 5 008 289 A (BERNSTEIN JOEL E) 16 April 1991 see claim 1 ---	1-16
X	WO 96 40079 A (UNIV EMORY) 19 December 1996 see page 22, line 1-3 -----	1-16

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

26 June 1998

Date of mailing of the international search report

08. 07. 1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Leherte, C

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/04912

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-10
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 1-10 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/04912

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4997853 A	05-03-1991	NONE	
US 5008289 A	16-04-1991	US 5134166 A	28-07-1992
WO 9640079 A	19-12-1996	US 5762963 A	09-06-1998
		AU 6170996 A	30-12-1996